恶性血液肿瘤患者侵袭性真菌感染防治进展

摘要/Abstract

摘要：

侵袭性真菌感染是恶性血液肿瘤患者常见的并发症之一，并导致较高的病死率，由此受到越来越多的关注。近十年来，随着诊疗模式的逐步完善，初级预防及二级预防的建立，新型抗真菌药物的应用，其发病率较前下降，但死亡率仍高。合理有效的防治可降低血液病患者真菌感染相关死亡率。该综述简述了恶性血液病患者中侵袭性真菌病预防、治疗策略的更新及目前真菌治疗存在的问题。

关键词: 血液肿瘤, 侵袭性真菌感染, 预防, 治疗

Abstract:

Invasive fungal infection is one of the common complications in patients with malignant blood tumor, which leads to a high mortality rate. Over the past decade, with the gradual improvement of the diagnosis and treatment, the establishment of primary and secondary prevention, and the application of new antifungal drugs, the incidence of the disease is lower than before, but the mortality is still high. Reasonable and effective prevention and treatment can reduce the mortality of fungal infection in patients with hematological malignancies. This review summarizes the prevention, treatment strategies and existing problems of invasive fungal disease in patients with hematological malignancies.

Key words: hematological malignancies, invasive fungal disease, prevention, treatment

中图分类号:

左微, 肖青. 恶性血液肿瘤患者侵袭性真菌感染防治进展[J]. 中国真菌学杂志, 2018, 13(4): 252-256.

ZUO Wei, XIAO Qing. Prevention and treatment for invasive fungal infection in patients with hematological malignancies[J]. Chinese Journal of Mycology, 2018, 13(4): 252-256.

参考文献

[1] Hahnast C, Glasmacher A, Mückter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006[J]. J Antimicrob Chemother, 2010, 65(4):761-768.
[2] Sun Y, Huang H, Chen J, et al. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy:a multicenter, prospective, observational study in China[J]. Tumour Biol, 2015, 36(2):757-767.
[3] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)[J]. 中华内科杂志, 2017, 56(6):453-459.
[4] Li Y, Liu M, Zhai B, et al. Primary antifungal prophylaxis:decrease of invasive fungal disease incidence and reduction of risk factors in hematological patients in a 5-year retrospective study[J]. Intern Med J.2018, 48(6):713-720.
[5] 吕海容,邓琦,李玉明,等. 急性白血病患者应用抗真菌药物预防侵袭性真菌病的疗效与安全性分析[J].中华医院感染学杂志,2016,26(7):1533-1535.
[6] Offner F, Cordonnier C,Ljungman P,et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation[J].Clin Infect Dis,1998,26(5):1098-1103.
[7] Doan TN, Kirkpatrick CM, Walker P, et al. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia:a multicenter audit[J]:J Antimicrob Chemother,2016, 71(2):497-505.
[8] Sun Y, Meng F, Han M, et al. Antifungal prophylaxis of patients undergoing allogeneic hematopoietic stem cell transplantation in China:a multicenter prospective observational study[J]. Biol Blood Marrow Transplant, 2015, 21(6):1117-1126.
[9] Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies:2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)[J].Ann Hematol,2018, 97(2):197-207.
[10] Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014[J]. Intern Med J,2014, 44(12b):1283-1297.
[11] Pagano L, Busca A, Candoni A, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies:SEIFEM recommendations[J]. Blood Rev,2017 31(2):17-29.
[12] Takaoka K, Nannya Y, Shinohara A, et al. A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma[J]. Ann Hematol,2014, 93(10):1637-1644.
[13] Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2016, 14(7):882-913.
[14] 曹江,江学维,章成,等.泊沙康唑抗侵袭性真菌感染文献计量分析[J]. 中华医院感染学杂志,2017, 27(24):5537-5540.
[15] Tormo M, Pérez-Martínez A, Calabuig M, et al. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy:A real-world comparison[J].Mycoses,2018, 61(3):206-212.
[16] Kontoyiannis DP,Marr KA,Park BJ,et al.Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients,2001-2006:overview of the Transplant Associated Infection Surveillance Network (TRANSNET) Database[J].Clin Infect Dis,2010,50(8):1091-1100.
[17] Shi JM, Pei XY, Luo Y, et al. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients:single center experiences of 12 years[J]. Zhejiang Univ Sci B,2015 16(9):796-804.
[18] Girmenia C,Aversa F,Busca A, et al. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne[J].Hematol Oncol,2013 31(3):117-126.
[19] Deng Q, Lv H, Lin XM, et al. Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies[J]. Curr Med Res Opin, 2018,34(7):1209-1216.
[20] 刘妍丽,杨时佳,吴思静,等.血液病患者肺部侵袭性真菌感染不同治疗方法的有效性研究[J]. 中华医院感染学杂志,2016,26(1):31-33.
[21] Cordonnier C, Pautas C, Maury S, et al. Empirical versus pre-emptive antifungal strategy in high-risk febrile neutropenic patients:a prospective randomized study[J]. Clin Infect Dis, 2009, 48(8):1042-1051.
[22] Valdez JM, Scheinberg P, Nunez O, et al. Decreased infection-related mortality and improved survival severe aplastic anemia in the past two decades[J].Clin Infect Dis,2011, 52(6):726-735.
[23] Tissot F,Agrawal S,Pagano L, et al.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica[J].2017, 102(3):433-444.
[24] Mousset S, Buchheidt D, Heinz W, Ruhnke M,et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)[J].Ann Hematol,2014, 93(1):13-32.
[25] Llinares P, Ruiz I, Zaragoza R,et al,EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients[J].Rev Iberoam Micol,2016, 33(4):206-215.
[26] 曾颖, 关焯梅, 黄婷婷. 棘白菌素类对比非棘白菌素类药物治疗侵袭性念珠菌感染和念珠菌血症的治愈率的系统评价[J].中国药房,2014(32):3038-3041.
[27] 万楚成,夏云金,张霞,等.重组人粒细胞集落刺激因子在恶性血液病合并真菌感染中应用的临床意义[J].中华医院感染学杂志, 2007,17(1):32-34.
[28] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis,2016, 62(4):e1-50.
[29] Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis,2016, 63(4):e1-e60.
[30] Wan L,Zhang Y,Lai Y, et al.Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation:a prospective multicenter randomized phase Ⅳ trial[J].J Clin Oncol,2015,33 (34):3999-4006.